HomeGILD • NASDAQ
Gilead Sciences, Inc.
$73.26
Pre-market:
$73.52
(0.35%)+0.26
Closed: Mar 19, 12:30:42 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed securityUS headquartered
Previous close
$73.69
Day range
$73.21 - $74.17
Year range
$71.37 - $87.87
Market cap
91.27B USD
Avg Volume
7.78M
P/E ratio
16.27
Dividend yield
4.20%
Primary exchange
NASDAQ
CDP Climate Change Score
B
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
7.11B-3.72%
Operating expense
3.01B-16.00%
Net income
1.43B-12.87%
Net profit margin
20.09-9.50%
Earnings per share
1.722.99%
EBITDA
3.22B9.88%
Effective tax rate
14.33%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
8.35B21.76%
Total assets
62.12B-1.66%
Total liabilities
39.38B-6.16%
Total equity
22.75B
Shares outstanding
1.25B
Price to book
4.02
Return on assets
10.18%
Return on capital
13.26%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
1.43B-12.87%
Cash from operations
2.17B-15.50%
Cash from investing
-727.00M-93.87%
Cash from financing
-1.10B29.28%
Net change in cash
380.00M-46.70%
Free cash flow
1.61B-30.80%
About
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the NASDAQ Biotechnology Index and the S&P 500. Gilead was founded in 1987 under the name Oligogen by Michael L. Riordan. The original name was a reference to oligonucleotides, small strands of DNA used to target genetic sequences. Gilead held its IPO in 1992, and successfully developed drugs like Tamiflu and Vistide that decade. In the 2000s, Gilead received approval for drugs including Viread and Hepsera, among others. It began evolving from a biotechnology company into a pharmaceutical company, acquiring several subsidiaries, though it still relied heavily on contracting to manufacture its drugs. The company continued its growth in the 2010s. However, it came under heavy scrutiny over its business practices, including extremely high pricing of drugs such as Sovaldi and Truvada in the United States relative to production cost and cost in the developing world. Wikipedia
Founded
Jun 22, 1987
Website
Employees
18,000
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu